Clinical trials
B Lymphoblastic Lymphoma clinical trials
Below are recruiting b lymphoblastic lymphoma clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT06533748RecruitingPhase 2
New treatment for kids with B-cell leukemia or lymphoma
This trial tests a new therapy plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma. It aims to improve outcomes for those with higher-risk features.
Charlotte, North CarolinaAges 1–18 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Gilbert, ArizonaAges 18 years+ - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Birmingham, AlabamaAges 12 years+ - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05333302RecruitingPhase 1
CAR-T treatment study for children and young adults with CD19 leukemia
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
Minsk, Minsk OblastAges 1–30 - NCT05366569Recruiting
CAR T-cell therapy for certain blood cancers after relapse
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
BresciaAges 18–70 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT05480449RecruitingPhase 1/Phase 2
Personalized CAR-T for children with high-risk B-ALL
This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.
Philadelphia, PennsylvaniaAges birth–29 years - NCT05541341Recruiting
Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Minas Gerais, Belo HorizonteAges birth–100 years - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21
Hear when a new B Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for b lymphoblastic lymphoma?
- Yes. Clin2 currently lists 139 recruiting b lymphoblastic lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a b lymphoblastic lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a b lymphoblastic lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.